The synergistic effect observed is independent of the mere PDL1 expression by tumour cells as combination of anti-PDL1/2 Abs with a PDL1 inducer (e.g. IFN-I) does not improve the outcome of therapy. This evidence concerns the gene CD274 and neoplasm.